Boehringer Ingelheim has bought Nerio Therapeutics, saying that it is adding a programme that – while still in preclinical development – could be a 'centrepiece' of its immuno-oncology pipeline.California, US-based Nerio is developing a series of small-molecule checkpoint inhibitors designed to rev up the immune system to fight cancers, focusing on compounds that target protein tyrosine phosphatases N1 and N2 (PTPN1 and PTPN2).According to Nerio, inhibiting these enzymes can disrupt a tumour's ability to evade the immune system and, according to co-founder and chief executive Sanford Madigan – also a partner at Avalon BioVentures which incubated Nerio since its founding in 2019 – its compounds have 'superior drug-like properties and provide a first-in-class opportunity.'The biotech has been preparing to file for approval to start clinical trials of its lead candidate later this year.It is the first acquisition for Boehringer since its takeover of T3 Pharma for just over $500 million last year and comes amid a busy period of dealmaking at the company as it builds its pipeline.

勃林格殷格翰（Boehringer Ingelheim）收购了Nerio Therapeutics，表示该公司正在增加一个项目，该项目虽然仍处于临床前开发阶段，但可能是其免疫肿瘤学管道的“核心”。总部位于美国加利福尼亚州的Nerio正在开发一系列小分子检查点抑制剂，旨在加速免疫系统对抗癌症，重点研究靶向蛋白酪氨酸磷酸酶N1和N2（PTPN1和PTPN2）的化合物。据Nerio称，抑制这些酶会破坏肿瘤逃避免疫系统的能力，据联合创始人兼首席执行官桑福德·麦迪根（SanfordMadigan）称，其化合物具有“优异的药物特性，提供了一流的机会”。桑福德·麦迪根也是自2019年成立以来孵化Nerio的AvalonBioventures的合伙人该生物技术公司一直在准备申请批准，以便在今年晚些时候开始其主要候选人的临床试验。这是勃林格自去年以略高于5亿美元的价格收购T3 Pharma以来的首次收购，目前该公司正在建设其管道，交易正处于繁忙时期。

Deals in the last few months – in cancer alone – have featured partnerships with OSE Immunotherapeutics, CBmed, T3Bio, and Enara Bio.The specific terms of the Nerio takeover have not been disclosed, including the upfront payment, but according to Boehringer could reach $1.3 billion if all conditions are met.'Securing the rights to Nerio Therapeutics' novel checkpoint inhibitors creates a broad panel of exciting new cancer treatment combination opportunities,' Paola Casarosa, a member of the board of managing directors at Boehringer, said in a statement.'This brings us a major step closer to our vision of transforming the lives of people living with cancer,' she added.Boehringer has made immuno-onco.

过去几个月，仅在癌症领域的交易就与OSE Immunotherapeutics、CBmed、T3Bio和Enara Bio建立了合作关系。Nerio收购的具体条款尚未披露，包括预付款，但据勃林格称，如果满足所有条件，可能达到13亿美元。”勃林格董事总经理保罗·卡萨罗萨（PaolaCasarosa）在一份声明中说，确保Nerio Therapeutics新型检查点抑制剂的使用权，创造了一系列令人兴奋的新癌症治疗组合机会她补充说：“这使我们离改变癌症患者生活的愿景又近了一大步。”。。